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LETTERS TO THE EDITOR
Treatment for M1a
Cancer of the
Esophagus May Not Be
Largely Palliative
To the Editor:
Trovo et al. undertook a retrospec-
tive review of 144 patients with esoph-
ageal cancer treated at Washington Uni-
versity who received neoadjuvant or
definitive chemoradiation. They sought
to determine the prognostic value of
celiac lymph node metastases. As the
management in these patients is contro-
versial, we commend the authors for con-
tributing to the literature on this important
subset of patients. However, we respect-
fully wish to clarify and comment on the
data, as well as their conclusions, as pre-
sented in the recent article in the Journal
of Thoracic Oncology.1
Some clinicians believe that the
presence of M1a disease, similar to T4
disease or distant metastases, precludes
curative treatment approaches. The
present report by Trovo et al. docu-
mented reasonably good survival out-
comes for a cohort of patients for whom
survival outcomes are often considered
to be quite dismal. For instance, the 2-
and 5-year overall survival was 36% and
15% in the M0 and 15% and 11% in
M1a groups, respectively (p  0.03).
For patients undergoing neoadjuvant
chemoradiation, the 2- and 5-year over-
all survival was 63% and 36% in the M0
and 37% and 13% in the M1a groups,
respectively (p  0.07). The authors
state that M1a status is a strong predictor
of poor outcome, and thus, treatment
should be considered largely palliative.
According to the authors, the
American Joint Committee on Cancer
staging system for esophageal carci-
noma divides the M classification into
M1a and M1b categories. They correctly
describe that for tumors of the lower
esophagus or gastroesophageal junction,
metastases in celiac nodes is classified
as M1a. However, they point out that
within their study group, 12 patients
(8%) had tumors located within the up-
per esophagus. For tumors of the
midthoracic or upper esophagus, the
M1a classification does not apply to ce-
liac nodes; in fact, these patients would
be considered M1b, a distinct clinical
entity. Furthermore, the authors do not
provide a definition for what was con-
sidered celiac nodes. Although the def-
inition may seem self-evident, it is actu-
ally quite contentious. It would be
helpful to know which lymph node sta-
tions of the celiac axis were considered
“celiac.” For instance, did the authors
follow the guidelines of stations 17–20
as outlined in the American Joint Com-
mittee on Cancer?
In addition, an omission of the
present report is the lack of comparison
of the M1a group to their group of pa-
tients with N1 disease. The authors out-
line the prognostic significance of M1a
disease as compared with M0 disease.
However, Table 1 shows that 61 patients
were N0 and 83 patients were N1. To
truly know the potential adverse prog-
nostic value of M1a disease, we think
that it is critical to compare with those
patients with any node positive. Stated
differently, in this retrospective study, is
the survival of stage IVa patients differ-
ent from stage III patients? Other au-
thors have shown that stage IVa pa-
tients, on the basis of M1a disease, have
prognosis similar to stage III patients.2–4
It would be very helpful if the authors
could “weigh-in” on this important issue
by providing survival data/curves for
node positive/celiac negative as well as
node positive/celiac positive patients. If,
in fact, the prognosis is similar, curative
intent treatment offered to fit patients
with stage III disease should be consid-
ered for those with stage IVa disease.
We believe the present report in
fact reinforces that the presence of M1a
disease should not absolutely exclude
patients from treatment with aggressive,
curative intent. Numerous reports, in-
cluding the present by Trovo et al., doc-
ument M1a survivals ranging from 10%
to 31.5%.4,5 Specifically, data from the
Mayo Clinic shows 10-year survival
rates of 7% in surgically treated pa-
tients.4 Thus, although the survival is
poor, a small but meaningful percentage
of patients display long-term survival.
Furthermore, until we know for sure that
M1a patients have a significantly poorer
outcome than those with stage III dis-
ease, these patients should not necessar-
ily be excluded from curative-intent
treatment strategies. Treatment may not
be largely palliative.
David Allen Schomas, MD
St. Lukes Cancer Institute
Kansas City, Missouri
Robert C. Miller, MD
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In Response:
In 2008, we published our retro-
spective experience of patients treated
with chemoradiation or chemoradiation
followed by surgery for locally ad-
vanced esophagus cancer.1 The main
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M1a esophagus cancer have a poorer
prognosis than patients with M0 disease.
We would like to thank Drs. Scho-
mas, Miller, and Quevedo for the oppor-
tunity to discuss and further clarify our
data. Their letter specifically requests
for additional data and comment on the
nonoperative patients treated with che-
moradiation. Our 2-year overall and dis-
ease-specific survival rates for patients
with M1a disease were 13% and 11%,
respectively, for this group.
To answer the question about a
comparison of patients staged as M1a
versus N1, we have included Figure 1
with this response letter. When staging
M1a versus M1b disease, we followed
the guidelines of the American Joint
Committee on Cancer staging system.
We did not attempt to differentiate sta-
tions 17 (left gastric), 18 (common he-
patic), and 20 (celiac) from each other.
These stations were collectively consid-
ered M1a disease for patients with lower
esophagus and gastroesophageal can-
cers. Surgical staging can clearly distin-
guish these separate nodal stations.
However, nodes in these stations appear
similar on computed tomography imag-
ing. Radiology reports do not and cannot
clearly distinguish this difference.
The main point of this query is
that patients with locally advanced
esophagus cancer, even stage M1a, de-
serve the opportunity to receive defini-
tive therapy because a few of them can
be cured by this approach, especially if
they fit within the highly selective cate-
gory of operative patients. First, we only
had 10 patients with M1a disease who
underwent esophagectomy. These
tended to be younger patients without
medical comorbidities who were fit
enough to receive trimodality therapy.
Most received chemoradiation alone.
We certainly agree that chemoradiation
can cure a few patients with locally
advanced esophageal cancer. However,
our survival outcomes with nonopera-
tive therapy for patients with M1a disease
clearly fall into the “dismal” category.
Although 13% of our patients survived 2
years, almost all the remaining patients
died of their esophagus cancer. For them,
the treatment was largely palliative.
Clearly, newer innovative therapy is
needed for this dreaded disease.
The treatment options for patients
with locally advanced esophagus cancer
have not changed since the 1980s. Ra-
diation Therapy Oncology Group 8501,
initiated in 1986, used cisplatin, 5-FU,
and 50 Gy in the chemoradiation arm of
this trial for inoperable patients.2 For
operable patients, a randomized trial
published by Walsh et al.3 used cispla-
tin, 5-FU, and 40 Gy preoperatively.
With the exception of some minor vari-
ations in radiation technique, both these
trials continue to drive therapy today.
Newer therapies are needed if we are to
improve outcome for these patients.
With respect to radiation therapy, trials
applying newer techniques to deliver in-
creased doses are warranted, such as
intensity modulation, image guidance,
and even proton therapy. Likewise, the
era of individualized therapy should ap-
ply to trials for patients with esophagus
cancer, mirroring distinctions being
made in therapies for lung and other
aerodigestive cancers.
Jeffrey Bradley, MD
Issam El Naqa, PhD
Department of Radiation Oncology
Mallinckrodt Institute of Radiology
Washington University School of Medicine
St. Louis, Missouri
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Staging in Lung Cancer
To the Editor:
The answer to the last frequently
asked question included in the Inter-
national Association for the Study of
Lung Cancer Staging Manual in Tho-
racic Oncology (Table 1)1 has been
met with concern by the members of
the Bronchogenic Carcinoma Cooper-
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FIGURE 1. Disease-specific survival comparison for N1 versus M1a status in pa-
tients with locally advanced carcinoma of the esophagus.
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